| | MEXICO CITY, Feb. 24, 2021 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2020. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS). The following tables provide an abridged Income Statement, in millions of Mexican pesos. The margin for each figure represents its ratio to net sales and the percentage change in the fourth quarter and full year 2020 as compared with the same audited period in 2019: | | Q4 2020 | % Sales | Q4 2019(2) | % Sales | Var. % | | Net Sales | 3,467.9 | 100.0% | 3,220.3 | 100.0% | 7.7% | | Gross Profit | 2,164.9 | 62.4% | 2,025.9 | 62.9% | 6.9% | | Operating Income | 690.0 | 19.9% | 519.0 | 16.1% | 33.0% | | EBITDA(1) | 729.4 | 21.0% | 563.0 | 17.5% | 29.6% | | Net Income | 334.2 | 9.6% | 35.6 | 1.1% | - | | | | | | | | | | FY 2020 | % Sales | FY 2019(2) | % Sales | Var. % | | Net Sales | 13,866.6 | 100.0% | 12,712.9 | 100.0% | 9.1% | | Gross Profit | 8,594.9 | 62.0% | 8,097.9 | 63.7% | 6.1% | | Operating Income | 2,777.1 | 20.0% | 2,330.8 | 18.3% | 19.1% | | EBITDA(1) | 2,932.0 | 21.1% | 2,471.7 | 19.4% | 18.6% | | Net Income | 1,477.8 | 10.7% | 764.5 | 6.0% | 93.3% | | | | | 1) | EBITDA defined as operating income before depreciation and amortization | | 2) | FY-2019 audit adjustments were allocated to Q4-2019 as presented herein. Variance between audited and unaudited figures was Ps. 43 million on Net Sales. Auditors recommended a reclassification of Ps. 94 million between Operating Expenses and Inflationary Results as part of hyperinflationary accounting in Argentina, this reclassification only impacted Earnings Before Taxes by Ps. 24 million. | Highlights - FY-2020 Sales increased by Ps. 1.15 billion; +9.1% year-on-year
- FY-2020 EBITDA grew +18.6% with a 21.1% margin; +170bps year-on-year margin expansion
- FY-2020 Net Income increased by Ps. 713.3 million; +93.3% year-on-year
- Q4-2020 Net Debt to EBITDA ratio closed at 1.47x
- Capex Investments for the twelve months ended December 31, 2020 reached Ps. 577.6 million.
For a full version of Genomma Lab Genomma Lab Internacional’s Fourth Quarter & Full Year 2020 Earnings Release, please visit: https://inversionistas.genommalab.com/en/financial-information/ CONFERENCE CALL INFORMATION: Genomma Lab will host a conference call on Thursday, February 25, 2021 to discuss these results at 11:00 a.m. Eastern Time / 10:00 Central Time (Mexico City Time). To access the call, please dial:
+1 877-407-0784 (From within the U.S.)
+1 201-689-8560 (From outside the U.S.) If you would prefer to receive a call rather than dialing in, please register via the following link. Please use this option 10-15 minutes prior to conference call start time: Call Me Link Participants who do not wish to be interrupted to have their information gathered may have provider dial out to them by clicking on the above link, filling in the information, and pressing the green phone button at the bottom. The phone number provided will be automatically called and connected to the conference without any interruption to the participant. (Please note: Participants will be joined directly to the conference and will hear hold music until the call begins. No confirmation message will be played when joined.) Webcast:
There will also be a live Audio Webcast of the event at: Genomma’s Q4' & Full Year 2020 Earnings Call Replay:
+1 844-512-2921 (U.S.)
+1 412-317-6671 (International)
Replay ID: 13715819
Available until March 4, 2021
About
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model. Genomma Lab’s shares are listed on the Mexican Stock Exchange under the ticker “LAB B” (Bloomberg: LABB:MM). Note on Forward-Looking Statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information:
Enrique González, Head of IR
Tel: +52 (55) 5081-0075
investor.relations@genommalab.com Barbara Cano, InspIR Group
Tel: +1 (646) 452-2334
barbara@inspirgroup.com  View original content:http://www.prnewswire.com/news-releases/genomma-lab-internacional-reports-fourth-quarter--full-year-2020-results-301235044.html
SOURCE Genomma Lab Internacional, S.A.B. de C.V. | |
